0001567619-22-008716.txt : 20220420 0001567619-22-008716.hdr.sgml : 20220420 20220420163223 ACCESSION NUMBER: 0001567619-22-008716 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220131 FILED AS OF DATE: 20220420 DATE AS OF CHANGE: 20220420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hawryluk Matthew CENTRAL INDEX KEY: 0001754470 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38663 FILM NUMBER: 22838519 MAIL ADDRESS: STREET 1: C/O GRITSTONE ONCOLOGY, INC. STREET 2: 5858 HORTON STREET, SUITE 210 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gritstone bio, Inc. CENTRAL INDEX KEY: 0001656634 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 871-6100 MAIL ADDRESS: STREET 1: 5959 HORTON STREET, SUITE 300 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: Gritstone Oncology, Inc. DATE OF NAME CHANGE: 20151023 4 1 doc1.xml FORM 4 X0306 4 2022-01-31 0 0001656634 Gritstone bio, Inc. GRTS 0001754470 Hawryluk Matthew C/O GRITSTONE BIO, INC. 5959 HORTON STREET, SUITE 300 EMERYVILLE CA 94608 0 1 0 0 See Remarks Common Stock 2022-01-31 4 A 0 21612 0 A 53351 D Stock Option (Right to Buy) 5.46 2022-01-31 4 A 0 129675 0 A 2032-01-30 Common Stock 129675 129675 D Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes 12,139 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,412 RSUs which vest over time measured from the grant date. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Executive Vice President and Chief Business Officer /s/ Rahsaan Thompson, Attorney-in-Fact for Matthew Hawryluk 2022-04-20